Vera Therapeutics (VERA) Debt to Equity (2021 - 2023)

Vera Therapeutics has reported Debt to Equity for 3 years, with the latest figure at $0.02 in Q1 2023.

• For the quarter ending Q1 2023, Debt to Equity fell 60.59% year-over-year to $0.02; the trailing twelve-month figure through Mar 2023 stood at $0.02 (down 60.59% YoY), and the FY2022 full-year result was $0.04, down 58.23% from the prior year.
• Debt to Equity for Q1 2023 stood at $0.02, down from $0.04 in the prior quarter.
• The five-year high for Debt to Equity was $0.09 in Q4 2021, with the low at $0.01 in Q3 2021.
• Historically, Debt to Equity has averaged $0.05 across 3 years, with a median of $0.05 in 2022.
• Annual changes were most pronounced in 2022 — Debt to Equity jumped 388.38% — and 2023, when it tumbled 60.59%.
• Vera Therapeutics' Debt to Equity stood at $0.09 in 2021, then slumped by 58.23% to $0.04 in 2022, then plunged by 46.15% to $0.02 in 2023.
• The last three Debt to Equity figures came in at $0.02 (Q1 2023), $0.04 (Q4 2022), and $0.06 (Q3 2022), per Business Quant data.